---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-323798"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2025-12-18T23:59:59+00:00"
generated_at: "2026-05-16T12:44:57.436772+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ovid reports Phase 1 safety and PK for OV350; oral KCC2 activator OV4071 on track for Q1 2026 filing

## Summary
- OV350 IV showed good safety; no treatment-related SAEs or lab findings in 16 healthy participants.
- PK as predicted; exploratory qEEG indicated central activity consistent with KCC2 modulation.
- OV4071 (oral) is 20-fold more potent; regulatory submission for Phase 1/1b expected Q1 2026, clinical start Q2 2026.
- Company will not advance OV350 IV further; resources directed to oral KCC2 activators OV4071 and OV4041.
- Most common AE was headache; nausea/vomiting in subset attributed to off-target pharmacology.

## SEC filing metadata
- accession: 0001193125-25-323798
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2025-12-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000119312525323798/0001193125-25-323798-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000119312525323798/d84904d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-323798
- JSON: https://secwatch.observer/filing/0001193125-25-323798.json
- Plain text: https://secwatch.observer/filing/0001193125-25-323798.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.